It seems I was wrong about Sellas Life Sciences and its experimental blood cancer immunotherapy.
On Tuesday, Sellas said the treatment, called galinpepimut-S, reduced the risk of death by 41% compared to standard treatment for patients with advanced acute myeloid leukemia (AML) – a result that met the primary endpoint of a phase 3 clinical trial, the company said.
In a column published in September, I predicted that galinpepimut would fail to prolong survival in the phase 3 study.

This article is reserved for STAT+ subscribers
Unlock this article, plus in-depth analysis, newsletters, premium events and news alerts.
Already have an account? Log in
See all packages
Gn bussni
